HRAS and hepatocellular carcinoma: Genetically, the DEN model is considered to be a good representation of HCC associated with a poor prognosis,32 but a caveat of this model is that over 80% of DEN‐initiated tumour samples carry an activating hotspot driver mutation in either Hras or Braf, which human HCC do not harbour during hepatocarcinogenesis.33